Defence Therapeutics Inc. (DTC.CN)
| Previous Close | 0.5200 |
| Open | 0.5500 |
| Bid | 0.5100 x N/A |
| Ask | 0.5600 x N/A |
| Day's Range | 0.5100 - 0.5700 |
| 52 Week Range | 0.4800 - 2.8500 |
| Volume | |
| Avg. Volume | 25,403 |
| Market Cap | 24.014M |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileDefence Announces Dr. Maxime Parisotto as CSO, Director of Science and Business Development
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that Dr. Maxime Parisotto has joined the Company as Chief Scientific Officer, Director of Science and Business Developmen
NewsfileDefence Announces Closing of Securities for Debenture Financing
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, announces that it has closed its offering of unsecured convertible debentures (the "New Debentures") for aggregate gross proceeds of CAD$1,476,0
